LYSOSOMAL ACID LIPASE DEFICIENCY TREATMENT MARKET ANALYSIS

The approval of innovative drugs by Food and Drug Administration (FDA) is expected to augment the growth of market. In 2015 the U.S. Food and Drug Administration (FDA) approved Alexion Pharmaceutical’s Kanuma (sebelipase alfa), an innovative enzyme replacement therapy (ERT). Kanuma is first approved therapy that treats the underlying cause of the disease. It is the only therapy for the treatment of LAL deficiency. As it is the only available therapy in market, kanuma is expected to have a significant market growth in the near future. According to the National Institute for Health and Care Excellence (NICE) 2016, around 50% of patients suffering from lysosomal acid lipase (LAL) deficiency have chances of liver complications, which includes cirrhosis or fibrosis and liver transplant. The increasing incidences of liver complications due to LAL deficiency is expected to increase demand for liver transplant, in turn fueling the growth of LAL deficiency treatment market over the forecast period. High cost and lack of awareness about diagnosis and treatment among people is the major restraint for the growth of Lysosomal Acid Lipase (LAL) Deficiency treatment market.